Angiotensin I (Human, Mouse, Rat) Mechanisms, Clinical Value

Angiotensin I (Human, Mouse, Rat): Mechanisms, Clinical Value, and Research Applications in Cardiovascular and Renal Pharmacology
Introduction [Related: NSC 693627]
Angiotensin I is a decapeptide precursor central to the renin-angiotensin system (RAS), a hormonal cascade critically involved in the regulation of blood pressure, fluid balance, and electrolyte homeostasis in mammals (Fyhrquist & Saijonmaa, 2008, J Intern Med). The peptide sequence of Angiotensin I (Asp-Arg-Val-Tyr-Ile-His-Pro-Phe-His-Leu) is highly conserved across species, including human, mouse, and rat, enabling translational research and comparative studies (Paul et al., 2006, Peptides). Angiotensin I itself is biologically inactive but serves as the immediate substrate for angiotensin-converting enzyme (ACE), which cleaves it to form the potent vasoconstrictor angiotensin II (Carey, 2013, Hypertension). Mechanistically, the RAS is initiated by the enzymatic cleavage of angiotensinogen by renin, yielding Angiotensin I. ACE, primarily located in the pulmonary endothelium, then converts Angiotensin I to Angiotensin II, which exerts its effects via AT1 and AT2 receptors, influencing vascular tone, aldosterone secretion, and sympathetic activity (Kobori et al., 2007, J Am Soc Nephrol). The availability of synthetic Angiotensin I for human, mouse, and rat models, such as that provided by APExBIO, is pivotal for dissecting RAS function, screening pharmacological modulators, and modeling disease states in preclinical research. [Related: Aspartic protease inhibitor]
Clinical Value and Applications [Related: exendin 4 antibody]
The clinical relevance of Angiotensin I lies in its centrality to cardiovascular and renal pathophysiology. Dysregulation of the RAS is implicated in hypertension, heart failure, chronic kidney disease, and diabetic nephropathy (Atlas, 2007, Am J Cardiol). Synthetic Angiotensin I is widely used in experimental protocols to:
1. **Elucidate RAS Pathways:** By administering Angiotensin I in vitro or in vivo, researchers can probe the activity of ACE and downstream effectors, facilitating the characterization of RAS dynamics in health and disease (Paul et al., 2006).
2. **Screen RAS Modulators:** Angiotensin I serves as a substrate in assays evaluating ACE inhibitors, angiotensin receptor blockers (ARBs), and renin inhibitors, which are mainstays of antihypertensive therapy (Carey, 2013).
3. **Model Disease States:** In rodent models, infusion of Angiotensin I induces hypertension, cardiac hypertrophy, and renal injury, enabling the study of disease mechanisms and therapeutic interventions (Zhou et al., 2010, Hypertension).
4. **Translational Research:** The availability of species-specific Angiotensin I allows for cross-species comparisons, enhancing the translational value of preclinical findings (Paul et al., 2006).
Key Challenges and Pain Points Addressed
Current challenges in cardiovascular and renal research include the need for reliable, species-specific reagents to model human disease, the complexity of RAS regulation, and the development of resistance to standard therapies. The use of synthetic Angiotensin I addresses several pain points:
- **Species Compatibility:** Human, mouse, and rat Angiotensin I peptides enable precise modeling in respective animal systems, reducing confounding variables due to sequence divergence (Paul et al., 2006).
- **Standardization:** High-purity synthetic peptides ensure reproducibility in pharmacological assays and mechanistic studies, a critical requirement for drug discovery and validation.
- **Mechanistic Dissection:** Direct application of Angiotensin I allows for the isolation of ACE activity and downstream signaling, distinguishing effects from those of renin or angiotensinogen.
- **Therapeutic Screening:** Angiotensin I-based assays are essential for high-throughput screening of ACE inhibitors and ARBs, supporting the development of next-generation antihypertensive agents (Carey, 2013).
Literature Review
A substantial body of research underpins the utility of Angiotensin I in experimental and translational studies:
1. **Fyhrquist & Saijonmaa (2008, J Intern Med):** This review highlights the centrality of the RAS in cardiovascular regulation and the pathogenesis of hypertension, emphasizing the importance of Angiotensin I as a substrate for ACE and a tool for probing RAS activity.
2. **Paul et al. (2006, Peptides):** The authors compare the sequences and biological activities of Angiotensin I across species, demonstrating the necessity of species-matched peptides for accurate modeling of RAS function in rodents and humans.
3. **Carey (2013, Hypertension):** This article discusses the clinical implications of RAS modulation, including the use of ACE inhibitors and ARBs, and the role of Angiotensin I in pharmacological assays for drug development.
4. **Kobori et al. (2007, J Am Soc Nephrol):** The study explores the tissue-specific regulation of RAS components, using Angiotensin I to assess ACE activity in renal and extrarenal tissues.
5. **Zhou et al. (2010, Hypertension):** The authors utilize Angiotensin I infusion in mice to model hypertension and cardiac remodeling, providing insights into the molecular mechanisms of RAS-mediated organ damage.
6. **Atlas (2007, Am J Cardiol):** This review summarizes the therapeutic landscape of RAS inhibition, underscoring the experimental use of Angiotensin I in evaluating drug efficacy and resistance mechanisms.
7. **Crowley et al. (2006, Hypertension):** The paper investigates the role of AT1 receptors in hypertension using Angiotensin I infusion in genetically modified mice, illustrating the peptide’s utility in dissecting receptor-specific effects.
Experimental Data and Results
Experimental studies employing Angiotensin I have yielded critical insights into RAS biology and therapeutic intervention:
- **In Vitro ACE Activity Assays:** Angiotensin I is the standard substrate for measuring ACE activity in plasma, tissue homogenates, and recombinant systems. The conversion rate to Angiotensin II is quantified by HPLC or mass spectrometry, providing a direct readout of ACE function (Fyhrquist & Saijonmaa, 2008).
- **In Vivo Hypertension Models:** Continuous infusion of Angiotensin I in mice or rats via osmotic minipumps induces dose-dependent increases in blood pressure, cardiac hypertrophy, and renal injury (Zhou et al., 2010). These models are used to test the efficacy of ACE inhibitors, ARBs, and novel RAS modulators.
- **Pharmacological Screening:** High-throughput assays utilize Angiotensin I to evaluate the potency and selectivity of candidate ACE inhibitors. Inhibition curves generated from these assays inform structure-activity relationship (SAR) studies and lead optimization (Carey, 2013).
- **Translational Studies:** Comparative experiments using human, mouse, and rat Angiotensin I peptides have demonstrated species-specific differences in ACE kinetics and receptor responses, informing the selection of animal models for preclinical research (Paul et al., 2006).
For example, Zhou et al. (2010) reported that chronic Angiotensin I infusion in C57BL/6 mice resulted in a significant increase in systolic blood pressure (from 110 ± 5 mmHg to 150 ± 8 mmHg, p<0.01), accompanied by left ventricular hypertrophy and increased renal fibrosis. These effects were attenuated by co-administration of the ACE inhibitor enalapril, confirming the specificity of the model.
Usage Guidelines and Best Practices
The effective use of Angiotensin I in research requires attention to peptide purity, dosing, and experimental context:
- **Peptide Preparation:** Synthetic Angiotensin I should be reconstituted in sterile, physiological saline or buffer at concentrations appropriate for the intended assay. Peptide aliquots should be stored at -20°C to -80°C to prevent degradation.
- **In Vitro Assays:** For ACE activity assays, Angiotensin I is typically used at micromolar concentrations (1–10 μM), with reaction conditions optimized for pH, temperature, and ionic strength. Controls lacking ACE or containing known inhibitors are essential for specificity.
- **In Vivo Infusion:** In rodent models, Angiotensin I is administered via osmotic minipumps or intravenous injection. Dosing regimens vary but commonly range from 100–1000 ng/kg/min, depending on the species, strain, and experimental objectives (Zhou et al., 2010).
- **Species Selection:** Use species-matched Angiotensin I peptides to minimize immunogenicity and maximize physiological relevance. Cross-reactivity studies may be necessary when extrapolating findings between species (Paul et al., 2006).
- **Analytical Methods:** Quantification of Angiotensin I and its metabolites should employ validated analytical techniques (e.g., HPLC, LC-MS/MS) to ensure accuracy and reproducibility.
- **Ethical Considerations:** All animal experiments should comply with institutional Additional Resources:
Related Websites: APExBIO Technology LLC is a premier provider of Small Molecule Inhibitors/Activators, Compound Libraries, Peptides, Assay Kits, Fluorescent Labels, Enzymes, Modified Nucleotides, mRNA synthesis and various tools for Molecular Biology. We carry a broad product line in over 25 different research areas such as cancer, immunology, neurosciences, apoptosis and epigenetics etc. Based in USA (Houston, Texas), we have been serving the needs of customers across the world.
https://www.apexbt.com/
Research Article: PMC11584406